CAMP4 Therapeutics Corporation
NASDAQ:CAMPBiotechnology
Healthcare
$4.00 +2.42%
+$0.10 today
- Market cap
- $251.02M
- Beta
- 0.08
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.49
52W Low $1.31High $7.75
Volume 0.21M
Average 0.10M
Income Statement
Follow revenue through to earnings.
Revenue
$3.50M
FY 2025 · Annual
+436.5% YoYOperating Income
-$52.06M
FY 2025 · Annual
Net Income
-$80.40M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Feb 2022 | FY2022 Feb 2023 | FY2023 Nov 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 295.84M | 0 | 350K | 652K | 3.5M |
| Cost of Revenue | 173.95M | 0 | 0 | 0 | 1.64M |
| Gross Profit | 121.89M | (947K) | 350K | 652K | 1.86M |
| Gross Margin | 41.2% | — | 100.0% | 100.0% | 53.1% |
| Research & Development | 28.44M | 34.77M | 40.62M | 38.82M | 38.2M |
| Selling, General & Admin | 100.9M | 10.23M | 11.61M | 14.92M | 17.36M |
| Operating Expenses | 134.76M | 45M | 52.23M | 53.74M | 53.92M |
| Depreciation & Amortization | 22.8M | 878K | 1.68M | 1.7M | 1.64M |
| EBITDA | 7.49M | (44.12M) | (50.2M) | (51.39M) | (50.42M) |
| EBITDA Margin | 2.5% | — | -14343.1% | -7882.2% | -1441.5% |
| Operating Income | (15.31M) | (45M) | (51.88M) | (53.09M) | (52.06M) |
| Operating Margin | -5.2% | — | -14822.6% | -8142.3% | -1488.3% |
| Interest Income | 0 | 0 | 2.81M | 1.33M | 2.17M |
| Interest Expense | 15.32M | 6.26M | 0 | 0 | 0 |
| Other Income / Expenses | (14.75M) | 809K | 2.59M | 1.3M | (28.34M) |
| Income Before Tax | (30.06M) | (44.19M) | (49.29M) | (51.79M) | (80.4M) |
| Pre-Tax Margin | -10.2% | — | -14083.1% | -7943.4% | -2298.5% |
| Income Tax Expense | 1.09M | 0 | 0 | 0 | 0 |
| Net Income | (31.15M) | (44.19M) | (49.29M) | (51.79M) | (80.4M) |
| Net Margin | -10.5% | — | -14083.1% | -7943.4% | -2298.5% |
| EPS (Basic) | (0.88) | (0.90) | (4.07) | (2.66) | (2.65) |
| EPS (Diluted) | (0.88) | (0.90) | (4.07) | (2.66) | (2.65) |
| 35.25M | 36.1M | 12.12M | 19.51M | 30.38M | |
| 35.25M | 36.13M | 12.12M | 19.51M | 30.38M |
CAMP Earnings Waterfall · TTM
NASDAQ:CAMP · Revenue to Net Income
Key Ratios
EPS$-2.27
Gross Margin76.9%
Net Margin-3933.1%
P/E Ratio-1.8
P/S Ratio301.8
Analysis
$3.9M of revenue converted into -$86.3M of net income for the selected period. Gross margin is 76.9% and net margin is -3933.1%, showing how much revenue survives after costs and taxes. EPS is $-2.27, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| SC 13G | SC 13G filing | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 |
How much revenue does CAMP generate?
CAMP4 Therapeutics Corporation (CAMP) reported $3.50M of revenue in fiscal 2025.
Is CAMP profitable?
CAMP4 Therapeutics Corporation (CAMP) reported -$80.40M of net income, with a net margin of -2298.5%.
Continue the stock analysis
Jump to another research area for this company.